Orthofix Medical Inc.: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Nov 4, 2025 and accepted by EDGAR at Nov 4, 2025, 09:01 ET.
Management's discussion and analysis
As filed, 31,477 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of Orthofix Medical Inc.'s (sometimes referred to as "we," "us" or "our") financial condition and results of operations should be read in conjunction with the discussion under the heading "Forward-Looking Statements" and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.
Executive Summary
We are a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. We offer a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics, and enabling technologies, including the 7D FLASH navigation system. To learn more, visit Orthofix.com and follow on LinkedIn. Information included on our website is not incorporated into, or otherwise creates a part of, this report.
Notable financial metrics in the third quarter of 2025 and recent achievements include the following:
- Third quarter 2025 net sales of $205.6 million, including sales from our M6 artificial cervical and lumbar discs, and pro forma net sales of $203.4 million, excluding sales from our M6 discs, representing an increase of 5% on a reported basis and 6% on a pro forma constant currency basis compared to third quarter 2024
- U.S. Spine Fixation net sales growth of 8% and procedure volume growth of 10% compared to third quarter 2024
- Bone Growth Therapies ("BGT") net sales of $61.2 million, representing growth of 6% compared to third quarter 2024
- Global Orthopedics net sales of $33.6 million, achieving constant currency growth of 6%, and U.S. Orthopedics net sales growth of 19% compared to third quarter 2024
- Third quarter 2025 net loss of $(22.8) million on a reported basis; Non-GAAP pro forma adjusted EBITDA of $24.6 million, with pro forma adjusted EBITDA margin expanding approximately 233 basis points compared to reported non-GAAP adjusted EBITDA for the third quarter 2024
- Seven consecutive quarters of adjusted EBITDA margin expansion; positive free cash flow of $2.5 million for the third quarter 2025
Results of Operations
The following table provides certain items in our condensed consolidated statements of operations as a percent of net sales:
(Unaudited)
| Three Months Ended September 30, 2025 (%) | 2024 (%) | Nine Months Ended September 30, 2025 (%) | 2024 (%) | |
|---|---|---|---|---|
| Net sales | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of sales | 27.8 | 31.3 | 32.0 | 32.0 |
| Gross profit | 72.2 | 68.7 | 68.0 | 68.0 |
| Sales, general, and administrative | 72.0 | 66.2 | 69.3 | 67.8 |
| Research and development | 7.2 | 8.8 | 8.4 | 9.4 |
| Acquisition-related amortization, impairment, and remeasurement | 1.3 | 3.3 | 3.9 | 3.3 |
| Operating loss | (8.3) | (9.6) | (13.6) | (12.5) |
| Net loss | (11.1) | (13.9) | (14.9) | (16.6) |
23
Net Sales by Product Category and Reporting Segment
Our operations are managed through two reporting segments: Global Spine and Global Orthopedics. The following table provides net sales by product category by reporting segment:
(Unaudited, U.S. Dollars, in millions)
| Three Months Ended September 30, 2025 | 2024 | Change | Constant Currency Change | |
|---|---|---|---|---|
| Bone Growth Therapies | $61.2 | $57.9 | 5.7% | 5.7% |
| Spinal Implants, Biologics and Enabling Technologies* | 108.6 | 102.9 | 5.6% | 5.6% |
| Global Spine* | 169.8 | 160.8 | 5.6% | 5.6% |
| Global Orthopedics | 33.6 | 30.5 | 10.1% | 5.9% |
| Pro forma net sales* | 203.4 | 191.3 | 6.3% | 5.7% |
| Impact from discontinuation of M6 product lines | 2.2 | 5.3 | (58.3%) | (58.6%) |
| Reported net sales | $205.6 | $196.6 | 4.6% | 3.9% |
(Unaudited, U.S. Dollars, in millions)
| Nine Months Ended September 30, 2025 | 2024 | Change | Constant Currency Change | |
|---|---|---|---|---|
| Bone Growth Therapies | $178.8 | $169.5 | 5.5% | 5.5% |
| Spinal Implants, Biologics and Enabling Technologies* | 317.8 | 308.3 | 3.1% | 3.1% |
| Global Spine* | 496.6 | 477.8 | 3.9% | 3.9% |
| Global Orthopedics | 96.7 | 88.4 | 9.4% | 7.4% |
| Pro forma net sales* | 593.3 | 566.2 | 4.8% | 4.5% |
| Impact from discontinuation of M6 product lines | 9.1 | 17.6 | (48.3%) | (48.3%) |
| Reported net sales | $602.4 | $583.8 | 3.2% | 2.9% |
* Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact of the Company's discontinuation of its M6 product lines. As pro forma net sales represent a Non-GAAP measure, see the reconciliation above of the Company's pro forma net sales to its reported figures under U.S. GAAP. The Company's reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines shown above.
Global Spine
Global Spine offers the following product categories:
- BGT, which manufactures, distributes, sells, and provides support services for market-leading devices used adjunctively in high-risk spinal fusion procedures and treats both nonunion and acute fractures in the orthopedic space. BGT uses distributors and a direct sales channel to sell its devices and provide associated support services to hospitals, healthcare providers, and patients in the U.S.
- Spinal Implants, Biologics, and Enabling Technologies is comprised of a broad portfolio of spine fixation implant products used in surgical procedures of the spine, which includes one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft market segments and image-guided surgical solutions to facilitate degenerative, minimally invasive, and complex surgical procedures. Spinal Implants, Biologics, and Enabling Technologies products are sold through a network of distributors and sales representatives to hospitals and healthcare providers on a global basis for Spinal Implants and Enabling Technologies, and primarily within the U.S. for Biologics.
Three months ended September 30, 2025 compared to 2024
Net sales of $172.1 million, an increase of $6.0 million or 3.6%
- BGT net sales increased $3.3 million, or 5.7%, largely driven by (i) increase in gross order volumes from our continued investment in our direct sales channels for both the spine and fracture markets and (ii) continued share growth of AccelStim
- Spinal Implants, Biologics, and Enabling Technologies net sales, excluding sales from the M6 product lines, increased $5.8 million, or 5.6%, primarily due to increased sales growth from new and existing high-volume distribution partners, particularly within Spinal Implants, which saw growth in its cervical, interbody, and thoracolumbar franchises; growth in these areas were partially offset by a decline in Biologics net sales
- Net sales from the M6 product lines decreased $3.1 million, or 58.3%, as a result of the announcement and discontinuation of the product lines to focus resources and investment in more profitable growth opportunities
Nine months ended September 30, 2025 compared to 2024
Net sales of $505.7 million, an increase of $10.3 million or 2.1%
- BGT net sales increased $9.3 million, or 5.5%, largely driven by (i) favorable changes in average sales prices, (ii) increase in gross order volumes from our continued investment in our direct sales channels for both the spine and fracture markets, and (iii) continued share growth of AccelStim
- Spinal Implants, Biologics, and Enabling Technologies net sales, excluding sales from the M6 product lines, increased $9.5 million, or 3.1%, primarily due to increased sales growth from new and existing high-volume distribution partners, particularly within Spinal Implants, which saw growth in its cervical, interbody, and thoracolumbar franchises; growth in these areas were partially offset by a decline in Biologics net sales
- Net sales from the M6 product lines decreased $8.5 million, or 48.3%, as a result of the announcement and discontinuation of the product lines to focus resources and investment in more profitable growth opportunities
Global Orthopedics
Global Orthopedics offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. Global Orthopedics sells its products through a global network of distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers.
Three months ended September 30, 2025 compared to 2024
Net sales of $33.6 million, an increase of $3.1 million or 10.1% on a reported basis and 5.9% on a constant currency basis
- U.S. growth of $1.6 million, or 18.5%, largely due to investments made in recent product launches, commercial execution within our sales channel, and from growth within our TrueLok and Fitbone product lines
- International sales increase $0.2 million, or 1.0% on a constant currency basis, primarily driven by sales from new products launched in the past three years and partially offset by large orders made by non-governmental organizations ("NGO") in the prior year
- Increase of $1.3 million due to movement in foreign currency exchange rates, which had a favorable impact on net sales in the quarter
Nine months ended September 30, 2025 compared to 2024
Net sales of $96.7 million, an increase of $8.3 million or 9.4% on a reported basis and 7.4% on a constant currency basis
- U.S. growth of $4.6 million, or 18.6%, largely due to investments made in recent product launches, commercial execution within our sales channel, and from growth within our TrueLok and Fitbone product lines
- International sales increase $2.0 million, or 3.2% on a constant currency basis, primarily driven by sales from new products launched in the past three years and partially offset by large orders made by NGOs in the prior year
- Increase of $1.7 million due to movement in foreign currency exchange rates, which had a favorable impact on net sales in the current year
Gross Profit
(Unaudited, U.S. Dollars, in thousands)
| Three Months Ended September 30, 2025 | 2024 | % Change | Nine Months Ended September 30, 2025 | 2024 | % Change | |
|---|---|---|---|---|---|---|
| Net sales | $205,634 | $196,606 | 4.6% | $602,401 | $583,834 | 3.2% |
| Cost of sales | 57,111 | 61,553 | (7.2%) | 192,726 | 186,790 | 3.2% |
| Gross profit | $148,523 | $135,053 | 10.0% | $409,675 | $397,044 | 3.2% |
| Gross margin | 72.2% | 68.7% | 3.5% | 68.0% | 68.0% | 0.0% |
Three months ended September 30, 2025 compared to 2024
Gross profit increased $13.5 million
- Increase in gross profit driven by net sales growth across BGT, Spinal Implants, Enabling Technologies, and Orthopedics product categories and from reduced headcount and overhead costs as a result of our decision to discontinue the M6 product lines
- Increase in gross profit of $3.0 million driven by a reduction of amortization of the inventory fair value step-up recognized in the SeaSpine Merger, which were amortized over the expected sales cycles of the acquired inventory and concluded in December 2024
- Increase of $1.6 million driven by a reduction in certain inventory-related charges, primarily due to portfolio rationalization decisions made in the prior year related to the SeaSpine Merger
Nine months ended September 30, 2025 compared to 2024
Gross profit increased $12.6 million
- Increase in gross profit driven by net sales growth across BGT, Spinal Implants, Enabling Technologies, and Orthopedics product categories
- Increase in gross profit of $9.1 million driven by a reduction of amortization of the inventory fair value step-up recognized in the SeaSpine Merger, which were amortized over the expected sales cycles of the acquired inventory and concluded in December 2024
- Partially offset by decrease in gross profit of $8.4 million resulting from an increase in inventory reserve expenses, primarily driven by our decision to discontinue the M6 product lines in order to focus resources and investments on more profitable growth opportunities
Sales, General, and Administrative Expense
(Unaudited, U.S. Dollars, in thousands)
| Three Months Ended September 30, 2025 | 2024 | % Change | Nine Months Ended September 30, 2025 | 2024 | % Change | |
|---|---|---|---|---|---|---|
| Sales, general, and administrative | $148,102 | $130,137 | 13.8% | $417,576 | $396,046 | 5.4% |
| As a percentage of net sales | 72.0% | 66.2% | 5.8% | 69.3% | 67.8% | 1.5% |
Three months ended September 30, 2025 compared to 2024
Sales, general, and administrative expense increased $18.0 million
- Increase of $13.2 million associated with certain legal matters, including our ongoing arbitration claims with former executives and the related securities class action complaints
- Increase of approximately $3.9 million in certain compensation-related costs, including commissions, due to increased headcount and net sales
- Increase of $0.5 million related to impairments incurred as a result of our decision to discontinue the M6 product lines
- Partially offset by a decrease of $0.8 million in integration-related costs, mostly stemming from severance expenses and professional fees incurred in the prior year
Nine months ended September 30, 2025 compared to 2024
Sales, general, and administrative expense increased $21.5 million
- Increase of $17.9 million associated with certain legal matters, including our ongoing arbitration claims with former executives and the related securities class action complaints
- Increase of approximately $9.1 million in certain compensation related costs, including commissions, due to increased headcount and net sales
- Increase of $7.8 million related to impairments of certain assets and losses incurred as a result of our decision to discontinue the M6 product lines
- Partially offset by a decrease of $10.5 million in succession charges and share-based compensation expense, primarily as a result of changes made in our executive leadership positions in the prior year
Research and Development Expense
(Unaudited, U.S. Dollars, in thousands)
| Three Months Ended September 30, 2025 | 2024 | % Change | Nine Months Ended September 30, 2025 | 2024 | % Change | |
|---|---|---|---|---|---|---|
| Research and development | $14,774 | $17,294 | (14.6%) | $50,474 | $54,835 | (8.0%) |
| As a percentage of net sales | 7.2% | 8.8% | (1.6%) | 8.4% | 9.4% | (1.0%) |
Three months ended September 30, 2025 compared to 2024
Research and development expense decreased $2.5 million
- Decrease of approximately $2.3 million as a result of our recent restructuring activities, mostly related to headcount, professional fees, and reduced spend for clinical studies as a result of our decision to discontinue the M6 product lines
- Decrease of $0.2 million in costs to comply with the European Union Medical Device Regulations
Nine months ended September 30, 2025 compared to 2024
Research and development expense decreased $4.4 million
- Decrease of approximately $7.9 million as a result of our recent restructuring activities, mostly related to headcount, professional fees, and reduced spend for clinical studies as a result of our decision to discontinue the M6 product lines
- Decrease of $0.9 million in costs to comply with the European Union Medical Device Regulations
- Partially offset by an increase of $4.1 million related to the impairments associated with our discontinuation of the M6 product lines and other organizational restructuring activities
Acquisition-related Amortization, Impairment, and Remeasurement
(Unaudited, U.S. Dollars, in thousands)
| Three Months Ended September 30, 2025 | 2024 | % Change | Nine Months Ended September 30, 2025 | 2024 | % Change | |
|---|---|---|---|---|---|---|
| Acquisition-related amortization, impairment, and remeasurement | $2,693 | $6,521 | (58.7%) | $23,547 | $19,305 | 22.0% |
| As a percentage of net sales | 1.3% | 3.3% | (2.0%) | 3.9% | 3.2% | 0.7% |
Acquisition-related amortization, impairment, and remeasurement consists of (i) amortization and impairment related to intangible assets acquired through business combinations or asset acquisitions and (ii) remeasurement of related contingent consideration arrangements, which are recognized immediately upon acquisition.
Three months ended September 30, 2025 compared to 2024
Acquisition-related amortization, impairment, and remeasurement decreased $3.8 million
- Decrease of $2.4 million associated with the remeasurement of a contingent consideration obligation with Lattus Spine LLC assumed in the SeaSpine Merger
- Decrease of $1.4 million in amortization expense of acquired intangibles, primarily as a result of our decision in the first quarter of 2025 to discontinue the M6 product lines and other product portfolio decisions
Nine months ended September 30, 2025 compared to 2024
Acquisition-related amortization, impairment, and remeasurement increased $4.2 million
- Increase of $12.3 million in amortization and impairment expense of acquired intangibles, primarily associated with the impairment of certain acquired intangible assets as a result of the discontinuation of the M6 product lines and other product portfolio decisions
- Decrease of $8.0 million associated with the remeasurement of a contingent consideration obligation with Lattus Spine LLC assumed in the SeaSpine Merger
Non-operating Income and Expense
(Unaudited, U.S. Dollars, in thousands)
| Three Months Ended September 30, 2025 | 2024 | % Change | Nine Months Ended September 30, 2025 | 2024 | % Change | |
|---|---|---|---|---|---|---|
| Interest expense, net | $(4,681) | $(5,210) | (10.2%) | $(13,137) | $(14,711) | (10.7%) |
| Other income/(expense), net | (535) | (2,528) | (78.8%) | 6,441 | (6,312) | (202.0%) |
Three months ended September 30, 2025 compared to 2024
Interest expense, net decreased $0.5 million
- Decrease of $0.5 million in interest expense resulting from favorable interest rates and amortization of debt issuance costs due to the refinancing of outstanding indebtedness in November 2024
Other income (expense), net increased $2.0 million
- Increase of $3.0 million associated with the impairment of certain investments measured at fair value in the third quarter of 2024
- Decrease of $1.7 million associated with foreign currency exchange rates, as we recorded a non-cash remeasurement loss of $0.6 million in the third quarter of 2025 compared to a gain of $1.2 million in the third quarter of 2024
Nine months ended September 30, 2025 compared to 2024
Interest expense, net decreased $1.6 million
- Decrease of $1.0 million in interest expense resulting from the amortization of debt issuance costs due to the refinancing of outstanding indebtedness in November 2024
- Decrease of $0.8 million associated with interest earned associated with certain Employee Retention Credit refunds received during the second quarter of 2025
- Partially offset by a decrease of $0.3 million of interest income as a result of the conversion of our former convertible loan with Neo Medical into preferred equity securities in the second quarter of 2024
Other income (expense), net increased $12.8 million
- Increase of $6.8 million associated with the impairment of certain investments measured at fair value in prior year and partially offset by a $1.7 million decrease associated with the gain recognized on conversion of the Neo Medical convertible loan into shares of equity
- Increase of $4.5 million associated with foreign currency exchange rates, as we recorded a non-cash remeasurement gain of $3.2 million in 2025 compared to a loss of $1.3 million in 2024
- Increase of $2.9 million associated with the receipt of Employee Retention Credit refunds received during the second quarter of 2025
Income Taxes
(Unaudited, U.S. Dollars, in thousands)
| Three Months Ended September 30, 2025 | 2024 | % Change | Nine Months Ended September 30, 2025 | 2024 | % Change | |
|---|---|---|---|---|---|---|
| Income tax expense | $533 | $751 | (29.0%) | $1,352 | $2,686 | (49.7%) |
| Effective tax rate | (2.4%) | (2.8%) | 0.4% | (1.5%) | (2.9%) | 1.4% |
Three months ended September 30, 2025 compared to 2024
- The decrease in tax expense compared to the prior year period is primarily due to decreased tax on foreign operations and tax benefit related to certain long-lived intangible assets
- The primary factor affecting our tax expense for the third quarter of 2025 compared to the prior year period was tax amortization on certain acquired intangibles and financial statement losses not benefited
Nine months ended September 30, 2025 compared to 2024
- The decrease in tax expense compared to the prior year period is primarily due to decreased tax on foreign operations and tax benefit related to certain long-lived intangible assets
- The primary factor affecting our tax expense for 2025 compared to the prior year period was tax amortization on certain acquired intangibles and financial statement losses not benefited
Liquidity and Capital Resources
Cash, cash equivalents, and restricted cash at September 30, 2025, totaled $65.9 million compared to $85.7 million at December 31, 2024. The following table presents the net change in cash, cash equivalents, and restricted cash for the nine months ended September 30, 2025, and 2024, respectively:
(Unaudited, U.S. Dollars, in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change | |
|---|---|---|---|
| Net cash provided by operating activities | $5,650 | $2,060 | $3,590 |
| Net cash used in investing activities | (23,727) | (26,445) | 2,718 |
| Net cash provided by (used in) financing activities | (3,163) | 19,222 | (22,385) |
| Effect of exchange rate changes on cash | 1,448 | (40) | 1,488 |
| Net change in cash and cash equivalents | $(19,792) | $(5,203) | $(14,589) |
The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities:
(Unaudited, U.S. Dollars, in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change | |
|---|---|---|---|
| Net cash provided by operating activities | $5,650 | $2,060 | $3,590 |
| Capital expenditures | (23,749) | (26,345) | 2,596 |
| Free cash flow | $(18,099) | $(24,285) | $6,186 |
Operating Activities
Cash flows from operating activities increased $3.6 million
- Decrease in net loss of $6.9 million
- Decrease of $5.1 million associated with non-cash gains and losses, such as depreciation, amortization, and impairments, inventory reserve expenses, the amortization of the inventory fair value step-up recognized in the SeaSpine Merger, remeasurement of contingent consideration obligations, changes in the valuation of investment securities, and share-based compensation expense
- Increase of $1.8 million relating to changes in working capital accounts, primarily attributable to changes in accounts payable, accounts receivable, and other current liabilities
Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 59 days at September 30, 2025, compared to 58 days at September 30, 2024 (calculated using third quarter net sales and ending accounts receivable). Inventory turns improved to 1.5 times as of September 30, 2025 compared to 1.2 times as of September 30, 2024 (calculated using trailing twelve-month cost of goods sold and ending net inventories).
Investing Activities
Cash flows used in investing activities decreased $2.7 million
- Decrease in spend of $2.6 million in capital expenditures
Financing Activities
Cash flows from financing activities decreased $22.4 million
- Decrease of $25.0 million associated with net borrowing activities related to our credit facilities
- Decrease of $4.0 million associated with contingent consideration payments
- Partially offset by an increase of $4.6 million in net proceeds from the issuance of common shares
- Further offset by a favorable change of $2.1 million in debt issuance costs associated with our credit facilities
Credit Facilities
On November 7, 2024, we entered into a $275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including Oxford, K2 HealthVentures LLC, and HSBC Ventures USA Inc. Certain of our foreign subsidiaries joined the Credit Agreement as guarantors shortly after the signing date. The Credit Agreement provides for a $160.0 million senior secured term loan (the "Initial Term Loan") and a $65.0 million senior secured delayed draw term loan facility (the "Term B Loan"). Draws under the Term B Loan are at our option from January 1, 2025 through June 30, 2026, subject to, among other conditions, our continued compliance with a pro-forma total debt-to-EBITDA leverage ratio of less than 4.0x. EBITDA is a non-GAAP financial measure which represents earnings before interest income (expense), income taxes, depreciation, amortization, and other negotiated addbacks and adjustments. In addition, at Oxford's discretion, an additional $50.0 million of draw capacity is available through January 1, 2029 (the "Term C Loan" and, together with the Term B Loan, the "Delayed Draw Term Loans" and collectively with the Initial Term Loan, the "Credit Facilities"). The Initial Term Loan and Delayed Draw Term Loans, to the extent ultimately drawn, will each mature in November 2029, following an interest-only payment period ending December 2028, and monthly amortization of principal and accrued interest between January 2029 and November 2029.
The Credit Agreement contains financial covenants requiring us to maintain a minimum level of liquidity at all times and to maintain a maximum total debt-to-EBITDA leverage ratio (measured on a quarterly basis) during the term of the facility. As of September 30, 2025, we were in compliance with all required financial covenants.
As of September 30, 2025, we had $160.0 million of outstanding borrowings under the Credit Agreement related to the Initial Term Loan. We have not made any borrowings under the Delayed Draw Term Loans as of September 30, 2025.
As of September 30, 2025, we had no borrowings on our available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($6.5 million).
Other
For information regarding contingencies, see Note 7 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.
Lattus Spine LLC ("Lattus") Contingent Consideration
Under the terms of a contingent consideration obligation in a purchase agreement assumed in the SeaSpine Merger, we may be required to make installment payments at certain dates based on future net sales of certain products (the "Lateral Products"). We made payments under this arrangement of $6.3 million during the nine months ended September 30, 2025. The estimated fair value of the remaining contingent consideration arrangement as of September 30, 2025, was $7.3 million; however, the actual amount ultimately paid could be higher or lower than the estimated fair value of the contingent consideration. As of September 30, 2025, we classified the remaining contingent consideration liability of $4.0 million and $3.3 million within other current liabilities and other long-term liabilities, respectively. For additional discussion of this matter, see Note 6 of the Notes to the Unaudited Condensed Consolidated Financial Statements.
Off-balance Sheet Arrangements
As of September 30, 2025, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.
Contractual Obligations
There have been no material changes in any of our material contractual obligations as disclosed in our Form 10-K for the year ended December 31, 2024.
Critical Accounting Estimates
Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are described in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no significant changes to our critical accounting estimates during the quarter covered by this report.
Recently Issued Accounting Pronouncements
See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued or adopted accounting pronouncements.
Non-GAAP Financial Measures
We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP financial measures used to supplement information regarding the performance and underlying trends of our business operations to facilitate comparisons to historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their U.S. GAAP results with non-GAAP financial measures.
The non-GAAP financial measures used in this filing may have limitations as analytical tools and should not be considered in isolation or as a replacement for U.S. GAAP financial measures. Some limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.
Constant Currency
Constant currency is calculated by using foreign currency rates from the comparable, prior year period to present net sales at comparable rates. Constant currency can be presented for numerous U.S. GAAP measures but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.
Free Cash Flow
Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Management uses free cash flow as an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.
Market risk
As filed, 123 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to our market risks as disclosed in our Form 10-K for the year ended December 31, 2024.
Controls and procedures
As filed, 1,367 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2025.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 157 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes from the risk factors disclosed in "Part I, Item 1A. Risk Factors" in our Form 10-K for the year ended December 31, 2024.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $205.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $602.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-07-01 to 2025-09-30 | $57.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2025-01-01 to 2025-09-30 | $192.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-07-01 to 2025-09-30 | $148.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-01-01 to 2025-09-30 | $409.7m | us-gaap:GrossProfit |
| Research and development | 3 months2025-07-01 to 2025-09-30 | $14.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-01-01 to 2025-09-30 | $50.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-07-01 to 2025-09-30 | $148.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2025-01-01 to 2025-09-30 | $417.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-07-01 to 2025-09-30 | −$17.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | −$81.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-07-01 to 2025-09-30 | $533.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-01-01 to 2025-09-30 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-07-01 to 2025-09-30 | −$22.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | −$90.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-07-01 to 2025-09-30 | −$0.57 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | −$2.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-07-01 to 2025-09-30 | −$0.57 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-01-01 to 2025-09-30 | −$2.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-07-01 to 2025-09-30 | 39,766,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-01-01 to 2025-09-30 | 39,468,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | $5.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-01-01 to 2025-09-30 | $23.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2025-09-30 | $62.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $394.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $832.6m | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $159.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $390.1m | us-gaap:Liabilities |
| Long-term debt | At period end2025-09-30 | $157.2m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2025-09-30 | $442.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-25-263670. Last ingested by Listed: Nov 13, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.